Hypogonadism and urologic surgeries: a narrative review
- PMID: 35958902
- PMCID: PMC9360521
- DOI: 10.21037/tau-22-308
Hypogonadism and urologic surgeries: a narrative review
Abstract
Background and objective: Previous studies indicated that the treatment of male hypogonadism can be beneficial for intraoperative and postsurgical outcomes. In this study, we aimed to determine the impact of male hypogonadism on urologic surgeries. We provided an overview of the key studies in the field with the focus on the outcomes of urologic surgeries in hypogonadal men with/without testosterone replacement therapy (TRT).
Methods: We performed a literature review in PubMed and Google Scholar databases for the most relevant articles pertaining to the outlined topics without placing any limitations on publication years or study designs. We included full-text English articles published in peer reviewed journals between January 1970 and March 2022.
Key content and findings: Androgen deficiency is a common finding after major urologic surgeries. Although guidelines recommend against TRT in men with prostate carcinoma, recent investigations showed no association between TRT and disease progression and recurrence. Indeed, recent evidence suggested that low androgen levels could be related to high grade prostate carcinoma and increased risk of upgrading from low to high grade disease. Investigations on the application of TRT in benign prostatic hyperplasia (BPH) patients also revealed contrasting results. While some studies suggested higher rates of prostate-related events in men who received TRT, others showed that TRT could alleviate urinary symptoms in hypogonadal men with BPH. Decreased testosterone level is commonly seen in bladder cancer patients. The treatment of perioperative androgen deficiency can reduce postoperative morbidities and lower the risk of recurrence in these patients. Low testosterone levels are observed in approximately half of the men who undergo artificial urinary sphincter (AUS) placement and can increase the risk of complications.
Conclusions: The role of testosterone treatment in patients with urologic diseases such as prostate carcinoma and BPH is controversial. Further investigations are needed to determine the impact of hypogonadism and TRT on the outcomes of urologic surgeries in patients with androgen deficiency.
Keywords: Hypogonadism; androgen deficiency; testosterone; urologic surgery.
2022 Translational Andrology and Urology. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-22-308/coif). JMH serves as an unpaid editorial board member of Translational Andrology and Urology from August 2021 to July 2023. The other authors have no conflicts of interest to declare.
Similar articles
-
Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.BJU Int. 2017 Feb;119(2):216-224. doi: 10.1111/bju.13578. Epub 2016 Aug 14. BJU Int. 2017. PMID: 27409523
-
Androgens and Urethral Health: How Hypogonadism Affects Postoperative Outcomes of Patients Undergoing Artificial Urinary Sphincter or Inflatable Penile Prosthesis Placement.Urology. 2024 Feb;184:266-271. doi: 10.1016/j.urology.2023.10.027. Epub 2023 Nov 14. Urology. 2024. PMID: 37972898
-
The role of testosterone in men's health: is it time for a new approach?Int Urol Nephrol. 2022 Nov;54(11):2767-2774. doi: 10.1007/s11255-022-03292-4. Epub 2022 Aug 1. Int Urol Nephrol. 2022. PMID: 35909146 Review.
-
Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.BJU Int. 2009 May;103(9):1179-83. doi: 10.1111/j.1464-410X.2008.08240.x. Epub 2008 Dec 23. BJU Int. 2009. PMID: 19154450
-
Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.Am J Health Syst Pharm. 2015 Apr 1;72(7):536-41. doi: 10.2146/ajhp140128. Am J Health Syst Pharm. 2015. PMID: 25788507 Review.
Cited by
-
Untreated hypogonadism and testosterone replacement therapy in hypogonadal men are associated with a decreased risk of subsequent prostate cancer: a population-based study.Int J Impot Res. 2024 Sep;36(6):655-658. doi: 10.1038/s41443-023-00820-3. Epub 2024 Jan 5. Int J Impot Res. 2024. PMID: 38177194
-
Artificial urinary sphincter and stricture disease: surgical principles in management.Transl Androl Urol. 2024 Aug 31;13(8):1717-1728. doi: 10.21037/tau-23-16. Epub 2023 Jul 11. Transl Androl Urol. 2024. PMID: 39280683 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources